Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

The primary aim of this study was to examine the effect of severe renal impairment (SRI) on the pharmacokinetics of lemborexant, a dual orexin receptor antagonist indicated for the treatment of insomnia. A phase 1 multicenter, single‐dose, open‐label, parallel‐group study was conducted in subjects w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacol Res Perspect
Hauptverfasser: Landry, Ishani, Aluri, Jagadeesh, Hall, Nancy, Filippov, Gleb, Dayal, Satish, Moline, Margaret, Reyderman, Larisa
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7945683/
https://ncbi.nlm.nih.gov/pubmed/33689224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.734
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge